InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, today announced the registration of legal entity in UK. InSysBio UK (INSYSBIO UK LIMITED) is located in Edinburgh.
InSysBio LLC (www.insysbio.com), a pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, announced today a collaboration with GSK, one of the world's leading research-based pharmaceutical and healthcare companies, for development of QSP platform of Chronic Obstructive Pulmonary Disease (COPD).
InSysBio LLC (www.insysbio.com) – pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development – announced today further collaboration with GSK - one of the world's leading research-based pharmaceutical and healthcare companies - to expand the previously developed QSP model of asthma.
InSysBio continues to investigate the mechanisms underlying Alzheimer’s disease (AD) using the quantitative systems pharmacology (QSP) modeling approach. The part of QSP model describing tau protein was published in the PLOS ONE journal. This is one of more than dozen InSysBio publications in AD area during last seven years.
Moscow, Russia, September 28, 2017. One must activate amyloid degradation as soon as possible to prevent the appearance of the protein plaques in brain under Alzheimer’s conditions. This conclusion was reached by scientists from the biotechnology company InSysBio, who created the first computer model of the disease. The final part of the work has been recently published in CPT: Pharmacometrics & Systems Pharmacology.
We use cookies (and other similar technologies) to collect data to improve your experience on our site.
By using our website, you agree to data collection as described in our website’s data collection policy.